Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Prothena Corporation plc - Ordinary Shares
(NQ:
PRTA
)
9.315
-0.085 (-0.90%)
Streaming Delayed Price
Updated: 1:08 PM EDT, Jun 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
187,026
Open
9.420
Bid (Size)
9.300 (100)
Ask (Size)
9.320 (200)
Prev. Close
9.400
Today's Range
9.190 - 9.580
52wk Range
5.830 - 11.80
Shares Outstanding
45,047,449
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Prothena (NASDAQ:PRTA) Smashes Q1 Estimates on $50 Million Milestone Payment, Shares Steady
↗
May 07, 2026
Via
Chartmill
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
May 07, 2026
From
Prothena Corporation plc
Via
Business Wire
Performance
YTD
+1.3%
+1.3%
1 Month
-7.4%
-7.4%
3 Month
+0.1%
+0.1%
6 Month
-3.9%
-3.9%
1 Year
+53.5%
+53.5%
More News
Read More
Prothena to Report First Quarter 2026 Financial Results on May 7
April 30, 2026
From
Prothena Corporation plc
Via
Business Wire
What's going on in today's after hours session
↗
April 27, 2026
Via
Chartmill
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
April 27, 2026
From
Prothena Corporation plc
Via
Business Wire
Prothena Corporation (NASDAQ:PRTA) Reports Q4 2025 Revenue Miss, Highlights Pipeline Progress and 2026 Cash Guidance
↗
February 19, 2026
Via
Chartmill
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Prothena Announces Leadership Team Updates
April 10, 2026
From
Prothena Corporation plc
Via
Business Wire
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
March 21, 2026
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
March 09, 2026
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces up to $100 Million Share Repurchase Plan
February 27, 2026
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
February 19, 2026
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
February 12, 2026
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Board of Directors Update
December 12, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
November 19, 2025
From
Prothena Corporation plc
Via
Business Wire
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker
↗
November 12, 2025
Via
Benzinga
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
November 11, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Corp PLC (NASDAQ:PRTA) Reports Q3 2025 Earnings and Key Pipeline Milestones
↗
November 06, 2025
Via
Chartmill
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
November 06, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Third Quarter 2025 Financial Results on November 6
October 30, 2025
From
Prothena Corporation plc
Via
Business Wire
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings)
↗
October 07, 2025
Via
Benzinga
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
October 01, 2025
From
Prothena Corporation plc
Via
Business Wire
Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
September 02, 2025
Via
Benzinga
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy
↗
August 29, 2025
Via
Benzinga
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
August 28, 2025
From
Prothena Corporation plc
Via
Business Wire
Frequently Asked Questions
Is Prothena Corporation plc - Ordinary Shares publicly traded?
Yes, Prothena Corporation plc - Ordinary Shares is publicly traded.
What exchange does Prothena Corporation plc - Ordinary Shares trade on?
Prothena Corporation plc - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Prothena Corporation plc - Ordinary Shares?
The ticker symbol for Prothena Corporation plc - Ordinary Shares is PRTA on the Nasdaq Stock Market
What is the current price of Prothena Corporation plc - Ordinary Shares?
The current price of Prothena Corporation plc - Ordinary Shares is 9.315
When was Prothena Corporation plc - Ordinary Shares last traded?
The last trade of Prothena Corporation plc - Ordinary Shares was at 06/25/26 01:08 PM ET
What is the market capitalization of Prothena Corporation plc - Ordinary Shares?
The market capitalization of Prothena Corporation plc - Ordinary Shares is 419.62M
How many shares of Prothena Corporation plc - Ordinary Shares are outstanding?
Prothena Corporation plc - Ordinary Shares has 420M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
